Mitsubishi Tanabe Pharma Corp. Newsletter
-
NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies
23 Oct 2025 07:00 GMT
… biotechs and big pharma with a focus on CNS drug discovery. She … Management at Shire Pharmaceuticals, Kissei Pharma Europe, Mitsubishi Tanabe, Takeda and Ono Pharma UK. Most … years' experience in biotech drug discovery and development having transitioned …
-
Mitsubishi Tanabe Pharma America to Present New Data on Investigational ND0612 at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
03 Oct 2025 13:43 GMT
… Twitter), Facebook and LinkedIn.
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC) is one … ;precision medicine" to provide drugs with high treatment satisfaction and …
-
2025 pharma M&A surges to $70 billion in major deals
11 Oct 2025 01:46 GMT
… ); and Bain Capital carved out Mitsubishi Tanabe Pharma for $3.3B in a … , deal flow, deal premiums, drug development, drug pricing, efimosfermin, efruxifermin, Eli Lilly …
-
Sanofi Korea transfers MS drug Aubagio rights to Mitsubishi Tanabe
15 Sep 2025 09:46 GMT
Sanofi Korea has granted Mitsubishi Tanabe Pharma Korea exclusive rights to market … arrangement, effective Sept. 1, gives Mitsubishi Tanabe control of sales and marketing …
-
Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers
21 Oct 2025 13:00 GMT
… Dewpoint’s proprietary condensate-modulating drug discovery platform, DPTX3186 uniquely forces … with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma Corporation, Dewpoint pushes the boundaries …
-
TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight
26 Sep 2025 00:41 GMT
… Analysis of Emerging TL1A Binder Drugs
Competitive Intelligence Analysis: SWOT … Therapeutics), Mitsubishi Tanabe Pharma, Roche (Genentech), Kiniksa Pharmaceuticals, Boehringer Ingelheim, aTyr Pharma, Kyorin Pharmaceutical, Cumberland Pharmaceuticals, among …
-
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
21 Oct 2025 12:00 GMT
… in submission of a new drug application (NDA) to the U … .S. Food and Drug Administration (FDA); the anticipated timing … on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual …
-
Pertussis Market Analysis and Forecast Report 2025-2035, Competitive Profiles of GlaxoSmithKline, Mitsubishi Tanabe Pharma, Sanofi, Sun Pharmaceutical, & ILiAD Biotechnologies. - ResearchAndMarkets.com
25 Jul 2025 14:54 GMT
DUBLIN--(BUSINESS WIRE)--Jul 25, 2025--
×
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
kAm%96 8=@32= A6CEFDD:D >2C<6E :?4=F56D G2C:@FD G244:?6 7@C>F=2E:@?D DF49 2D H9@=6\46== G244:? …
-
Mitsubishi Tanabe Pharma forms targeted alpha therapy collaboration in Japan
11 Jul 2025 13:00 GMT
Cancer
Mitsubishi Tanabe Pharma Corp., Veneno Technologies Co. Ltd. and Alpha Fusion Co. Ltd. have initiated a joint research collaboration in Japan to develop cancer drugs using targeted alpha therapy (TAT).
BioWorld Science Collaboration Cancer
-
<![CDATA[Medicare Expenditures in the First Year of Amyotrophic Lateral Sclerosis Diagnosis]]>
20 Oct 2025 17:07 GMT
… patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an … and Radicava ORS. Prescribing information. Mitsubishi Tanabe Pharma America; 2022. Accessed December 20 …
About
© 1995-2025